Iradimed Corporation (IRMD), a maker of MRI-compatible intravenous infusion systems, saw its shares jump 9.26% on Tuesday following the release of an earnings report that underscored a remarkable and consistent growth trajectory.
The company announced that its revenue for the fourth quarter of 2025 reached $22.7 million, a 17% increase from the same period last year. This result marks the 18th consecutive quarter in which Iradimed has achieved a new all-time high in revenue, demonstrating remarkable consistency in its top-line growth.
Profitability also saw a significant boost. Non-GAAP net income for the quarter soared 23% year-over-year to nearly $7.0 million, or $0.54 per share. This earnings figure comfortably exceeded the Wall Street consensus estimate of $0.48 per share.
The record performance was fueled in part by the quarter’s rollout of a key new product, the 3870 intravenous infusion pump, which began shipping to customers. This launch strengthens Iradimed’s position in its niche market of MRI-compatible medical devices.
Further cheering investors, the company announced a raise to its quarterly dividend. The payout will increase from $0.17 to $0.20 per share. The enhanced dividend is scheduled for distribution on March 6 to shareholders of record as of February 23.
Looking ahead, management provided optimistic guidance for the full year 2026. The company forecasts revenue in the range of $91 million to $96 million, with non-GAAP net income expected between $20.6 million and $22.1 million. Both ranges represent a substantial increase over the $73 million in revenue and $1.66 per share in adjusted net income reported for 2024.
For growth-focused investors, Iradimed’s story is one of executing a proven playbook. The company has turned record-setting performance into a “new normal,” building a strong foundation for future competition in its specialized segment of the medical device industry.
